Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toca 511 and Toca FC in Advanced Solid Tumors or Lymphoma
NCT02576665Phase 1Terminated
- Sponsor
- Tocagen
- Start
- Jul 2016
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vocimagene amiretrorepvec in colorectal cancer (CRC), triple-negative breast cancer (TNBC), pancreatic cancer (PC) and 9 more, sponsored by Tocagen. Primary endpoint: Changes from baseline in immune activity in tumor and peripheral blood. Started Jul 2016; status: terminated.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02576665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576665.